An empirical study of foreign direct investments of Malaysian multinationals: wholly-owned subsidiaries and international joint ventures by Abdul Ghani, Ahmad Bashawir, Subhan, Muhammad, Tull, Malcolm

“…Our findings suggest Malaysian multinationals are strongly influenced by their strategic motivations and their desire to exploit synergies in their choice of entry mode between wholly-owned subsidiaries and international joint ventures…”
Get full text

The determinants of hub efficiency in Scope International (Malaysia) Sdn Bhd (Wholly owned subsidiary of Standard Chartered Bank) / Wafi Syakir Abdul Aziz by Abdul Aziz, Wafi Syakir

Get full text

Capital structure of foreign affiliates and the investment decision: two questions to consider by Fernando Merino

Subjects: Get full text

Experiential Insights from Managing Joint Ventures in Indonesia : Reflection on Past Lessons and Future Challenges by Teddy Pawitra

Subjects: Get full text

357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refra... by Cheryl Li, Lei Shen, Sabrina Collins, Adarsh Joshi, Subhasree Das, Kaveri Suryanarayan, Dean Bottino, Michael Curley, Dannie Wang, Michael Abadier, Ryan Larson, Xavier Parot

microRNA‐122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma by Julja Burchard, Chunsheng Zhang, Angela M Liu, Ronnie T P Poon, Nikki P Y Lee, Kwong‐Fai Wong, Pak C Sham, Brian Y Lam, Mark D Ferguson, George Tokiwa, Ryan Smith, Brendan Leeson, Rebecca Beard, John R Lamb, Lee Lim, Mao Mao, Hongyue Dai, John M Luk

Get full text

Chromosome 20q Amplification Regulates Response to Kinesin-5 Inhibitor by Aimee L. Jackson, Mao Mao, Sumire Kobayashi, Teresa Ward, Matthew Biery, Hongyue Dai, Steven R. Bartz, Peter S. Linsley

Get full text

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation s... by Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael J. Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang, Xiaoquan Zhang, Hui Wang, Helgi van de Velde, Paul G. Richardson, Philippe Moreau

Get full text

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial by Xiaofei Zhou, Sharon Friedlander, Erik Kupperman, Farhad Sedarati, Shingo Kuroda, Zhaowei Hua, Ying Yuan, Yuka Yamamoto, Douglas V. Faller, Kazue Haikawa, Katsuhiko Nakai, Sharon Bowen, Yi Dai, Karthik Venkatakrishnan

Get full text

Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myel... by Moshe Levy, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava, Daniel Naranjo, Jing Xu, Qisu Zhang, Mehul Dalal

Get full text

siRNA-optimized Modifications for Enhanced In Vivo Activity by Denise M Kenski, Gabor Butora, Aarron T Willingham, Abby J Cooper, Wenlang Fu, Ning Qi, Ferdie Soriano, Ian W Davies, W Michael Flanagan

Get full text

Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee by James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes

Get full text

Lipids as Emerging Biomarkers in Neurodegenerative Diseases by Justin Wei, Li Chin Wong, Sebastian Boland

Get full text

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia,... by Jill A. Bell, Aaron Galaznik, Farrah Pompilus, Sara Strzok, Rafael Bejar, Fatima Scipione, Robert J. Fram, Douglas V. Faller, Stefan Cano, Patrick Marquis

Get full text

Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease by Rekha Raghunathan, Kathleen Turajane, Li Chin Wong

Get full text

Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response by Yosuke Sato, Yu Fu, Hong Liu, Min Young Lee, Michael H. Shaw

Get full text

An organizational economics approach to the existence of sharecropping by Jiancai PI

“…Similar to a multinational enterprise's decision of whether to enter a joint venture or to choose a wholly owned subsidiary, we can see sharecropping as a joint venture and a fixed rent contract as a wholly owned subsidiary when we stand in the tenant's position. …”
Get full text

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer... by Yanyan Zhu, Milenka Jean‐Baptiste, William R. Lenderking, Jill A. Bell, Dennis A. Revicki, Huamao M. Lin, Rachael Brake, Bryce B. Reeve

Get full text

Real‐world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States by Lia N. Pizzicato, Vijay R. Nadipelli, Samuel Governor, Jianbin Mao, Stephan Lanes, John Butler, Rebecca S. Pepe, Hemant Phatak, Karim El‐Kersh

Get full text

Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee by James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes

Get full text